Nuclear factor, erythroid 2 (NFE2)

Nuclear factor, erythroid 2 (NFE2) is a basic leucine zipper (bZIP) transcription factor in the Cap ‘n’ Collar (CNC) family, predominantly expressed in hematopoietic cells such as erythroid cells, megakaryocytes, and mast cells. NFE2 forms heterodimers with small MAF proteins (MAFK, MAFG, MAFF), which then bind to regulatory elements in genes involved in globin production, heme biosynthesis, and platelet formation. Its principal functions are regulating megakaryocyte maturation, driving platelet biogenesis, and influencing globin gene expression through chromatin remodeling and transactivation, often in coordination with transcription factors like GATA1 and RUNX1. Knockout models demonstrate its essential role in platelet formation, while its effects on erythroid maturation may be partially compensated by other CNC factors. NFE2 is implicated in hematological disorders, including erythroleukemia, thrombocytopenia, and polycythemia. It has recognized posttranslational modifications (SUMOylation, ubiquitination, phosphorylation) that fine-tune its activity. NFE2’s restricted tissue distribution and critical regulatory roles make it a key molecular target in hematopoietic research and disease, with some suggestion of function in non-hematopoietic tissues such as the trophoblast and bone.

Other names

Transcription factor NF-E2 45 kDa subunitNF-E2Leucine zipper protein NF-E2Nuclear factor, erythroid-derived 2 45 kDa subunitp45 NF-E2NF-E2, p45Nuclear factor (erythroid-derived 2) 45 kDa subunit

Drugs or interventions that modulate NFE2 activity would likely affect its transcriptional regulation of erythroid and megakaryocytic genes, impacting platelet production and globin expression. This mechanism is primarily relevant in experimental contexts such as gene editing or transcription factor modulation.